190 related articles for article (PubMed ID: 3081767)
1. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
Russell NH; Hoffbrand AV; Bellingham AJ
Leuk Res; 1986; 10(3):325-9. PubMed ID: 3081767
[TBL] [Abstract][Full Text] [Related]
2. Selective toxicity of purine nucleosides to human leukaemic cells.
Piga A; Ganeshaguru K; Green ES; Sheridan B; Hoffbrand AV
Adv Exp Med Biol; 1989; 253B():291-8. PubMed ID: 2514591
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
4. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of purine nucleoside phosphorylase by 8-aminoguanosine: selective toxicity for T lymphoblasts.
Kazmers IS; Mitchell BS; Dadonna PE; Wotring LL; Townsend LB; Kelley WN
Science; 1981 Dec; 214(4525):1137-9. PubMed ID: 6795718
[TBL] [Abstract][Full Text] [Related]
6. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
[TBL] [Abstract][Full Text] [Related]
7. The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2'deoxycoformycin.
Russell NH; Carron J; Hoffbrand AV; Bellingham AJ
Leuk Res; 1985; 9(2):315-9. PubMed ID: 3872974
[TBL] [Abstract][Full Text] [Related]
8. B cells as well as T cells form deoxynucleotides from either deoxyadenosine or deoxyguanosine.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Clin Exp Immunol; 1984 Apr; 56(1):39-48. PubMed ID: 6424986
[TBL] [Abstract][Full Text] [Related]
9. Lack of inhibition of purine nucleoside phosphorylase and adenosine deaminase in patients treated with azathioprine.
Maddocks JL; Al-Safi SA
Br J Clin Pharmacol; 1985 Jan; 19(1):108-11. PubMed ID: 3919749
[TBL] [Abstract][Full Text] [Related]
10. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
Smith CM; Belch A; Henderson JF
Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
[No Abstract] [Full Text] [Related]
11. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
12. Enzymes of purine metabolism in lymphoid neoplasms, clinical relevance for treatment with enzyme inhibitors.
Ho AD; Ganeshaguru K
Klin Wochenschr; 1988 Jun; 66(11):467-74. PubMed ID: 2841534
[TBL] [Abstract][Full Text] [Related]
13. Inhibitors of purine nucleoside phosphorylase: effects of 9-deazapurine ribonucleosides and synthesis of 5'-deoxy-5'-iodo-9-deazainosine.
Stoeckler JD; Ryden JB; Parks RE; Chu MY; Lim MI; Ren WY; Klein RS
Cancer Res; 1986 Apr; 46(4 Pt 1):1774-8. PubMed ID: 3081256
[TBL] [Abstract][Full Text] [Related]
14. Decreased methionine synthesis in purine nucleoside-treated T and B lymphoblasts and reversal by homocysteine.
Boss GR; Pilz RB
J Clin Invest; 1984 Oct; 74(4):1262-8. PubMed ID: 6332827
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
16. Differential cytotoxicity of deoxyguanosine and 8-aminoguanosine for human leukemic cell lines and normal bone marrow progenitor cells.
de Fouw NJ; Ma DD; Michalevicz R; Gray DA; Hoffbrand AV
Hematol Oncol; 1984; 2(2):189-97. PubMed ID: 6430777
[TBL] [Abstract][Full Text] [Related]
17. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
[No Abstract] [Full Text] [Related]
18. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
19. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Haleem A; Kurtzberg J; Olsen GA; Rhinehardt-Clark A; Leslie DS; Ray L; Smith CA; Peters WP; Haynes BF; Bast RC
Cancer Res; 1987 Sep; 47(17):4608-12. PubMed ID: 3113721
[TBL] [Abstract][Full Text] [Related]
20. Studies on the effect of deoxyadenosine on deoxycoformycin-treated myeloid and lymphoid stem cells.
Aye MT; Dunne JV; Yang WC
Blood; 1982 Oct; 60(4):872-6. PubMed ID: 6981441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
